ArticleNeuro-oncology advances

Correction to: Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis.

No numbers read from the abstract.

Not cited yet